Table 3.
BMS treatment outcomes.
| Group | Results |
|---|---|
| Total (n = 57) | No improvement VAS—15 (26.3%), improvement VAS—38 (66.7%), healing—4 (7%) VAS before treatment 6.07 ± 1.9, after treatment 4.03 ± 2.5; p < 0.0000 |
| First group (n = 28) | No improvement VAS—5 (17.9%, without worsening VAS), improvement VAS—20 (71.4%), healing—3 (10.7%) VAS before treatment 6.57 ± 1.5, after treatment 3.07 ± 1.82; p < 0.0000 |
| Second group (n = 29) | No improvement VAS—10 (34.4%, including 4 with worsening VAS—13.8%), improvement VAS—18 (62.1%), healing—1 (3.4%) VAS before treatment 5.59 ± 2.1 1, after treatment 4.97 ± 2.71 2; p = 0.016 |
1 VAS difference between groups before treatment p = 0.054; 2 difference in VAS values between groups after treatment p = 0.0055.